HemoSphere Bio, the German company known for its small presence in blood therapies, proceeds in its goal to become the lead player in Hemophilia A treatment in Europe. Phase II clinical trials with the candidate Octomab were just concluded successfully.
In its latest official statement, the company now confirmed the rumors about a new campaign to bring Octomab to the public. The next round of clinical trials is being prepared to prove the innovative effects of this drug. Official channels for new study participants are expected to open soon. Interns further claimed that HemoSphere Bio increased funding for unofficial programs to expand connections to big players of pharma and government. These steps emphasize the company’s urgence to get approval by the EMA within the next decade.
Erstelle deine eigene Website mit Webador